PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
1-Year Return
33.7%
This Quarter Return
+3.03%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$751M
AUM Growth
-$32.5M
(-4.2%)
Cap. Flow
+$3.19M
Cap. Flow
% of AUM
0.42%
Top 10 Holdings %
Top 10 Hldgs %
35.59%
Holding
104
New
11
Increased
46
Reduced
31
Closed
15
Top Buys
| 1 |
Gilead Sciences
GILD
|
$22.7M |
| 2 |
Stryker
SYK
|
$17.9M |
| 3 |
McKesson
MCK
|
$13.1M |
| 4 |
Viridian Therapeutics
VRDN
|
$12.7M |
| 5 |
Edwards Lifesciences
EW
|
$10.8M |
Top Sells
| 1 |
Teleflex
TFX
|
$23.8M |
| 2 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$16.4M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$12.7M |
| 4 |
Boston Scientific
BSX
|
$9.81M |
| 5 |
Eli Lilly
LLY
|
$9.43M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Replimune Group
REPL
$445M
| $10.5M | 1.4% |
869,759
+106,012
| +14% | +$1.28M |
|
27
RxSight
RXST
$344M
| $10.3M | 1.38% |
300,698
+116,378
| +63% | +$4M |
|
28
Edgewise Therapeutics
EWTX
$1.53B
| $10.2M | 1.36% |
381,173
-275,897
| -42% | -$7.37M |
|
29
UnitedHealth
UNH
$280B
| $10.1M | 1.35% |
+20,000
| New | +$10.1M |
|
30
Nurix Therapeutics
NRIX
$695M
| $10M | 1.34% |
532,172
+93,201
| +21% | +$1.76M |
|
31
Vaxcyte
PCVX
$4.07B
| $9.51M | 1.27% |
116,138
-14,111
| -11% | -$1.16M |
|
32
Alnylam Pharmaceuticals
ALNY
$59.6B
| $9.1M | 1.21% |
38,672
+13,187
| +52% | +$3.1M |
|
33
Castle Biosciences
CSTL
$665M
| $8.12M | 1.08% |
304,629
+8,558
| +3% | +$228K |
|
34
LivaNova
LIVN
$3.16B
| $8.1M | 1.08% |
174,934
+73,205
| +72% | +$3.39M |
|
35
CVS Health
CVS
$93.3B
| $8.08M | 1.08% |
+180,000
| New | +$8.08M |
|
36
PTC Therapeutics
PTCT
$4.47B
| $8.01M | 1.07% |
177,368
-17,632
| -9% | -$796K |
|
37
QuidelOrtho
QDEL
$1.89B
| $7.81M | 1.04% |
175,415
+100,415
| +134% | +$4.47M |
|
38
Xenon Pharmaceuticals
XENE
$2.96B
| $7.57M | 1.01% |
193,004
+1,346
| +0.7% | +$52.8K |
|
39
Amicus Therapeutics
FOLD
$2.45B
| $7.39M | 0.98% |
784,376
+179,058
| +30% | +$1.69M |
|
40
Syndax Pharmaceuticals
SNDX
$1.37B
| $6.97M | 0.93% |
526,973
+18,690
| +4% | +$247K |
|
41
DexCom
DXCM
$31.7B
| $6.11M | 0.81% |
78,550
+7,962
| +11% | +$619K |
|
42
Axogen
AXGN
$721M
| $6.03M | 0.8% |
365,703
-47,185
| -11% | -$778K |
|
43
Keros Therapeutics
KROS
$628M
| $4.98M | 0.66% |
314,541
-107,241
| -25% | -$1.7M |
|
|
BCYC
44
Bicycle Therapeutics
BCYC
$475M
| $4.93M | 0.66% |
352,481
-92,915
| -21% | -$1.3M |
|
45
uniQure
QURE
$934M
| $4.86M | 0.65% |
+275,000
| New | +$4.86M |
|
46
Jazz Pharmaceuticals
JAZZ
$7.81B
| $4.65M | 0.62% |
37,751
-34,505
| -48% | -$4.25M |
|
47
Terns Pharmaceuticals
TERN
$597M
| $4.59M | 0.61% |
829,105
+283,354
| +52% | +$1.57M |
|
48
Teva Pharmaceuticals
TEVA
$21.3B
| $4.34M | 0.58% |
196,805
-88,489
| -31% | -$1.95M |
|
49
Ultragenyx Pharmaceutical
RARE
$3.01B
| $4.21M | 0.56% |
100,159
-9,309
| -9% | -$392K |
|
50
Veracyte
VCYT
$2.43B
| $3.97M | 0.53% |
100,301
-28,959
| -22% | -$1.15M |
|